MiMedx Group, Inc. announced the appointment of Matt Notarianni as Head of Investor Relations (IR), effective immediately. Mr. Notarianni joins MIMEDX with over 15 years of healthcare-focused Wall Street and IR experience, most recently serving as head of IR for Cerus Corporation. Jack Howarth, MIMEDX Senior Vice President of Investor Relations, will continue to support the MIMEDX IR function until his planned retirement at the end of this year. Prior to his role at Cerus, Mr. Notarianni was at Immucor, Inc. from 2012-2021, serving most recently as Senior Director, Corporate Development &External Communications. He began his career as an equity
research analyst at Robert W. Baird &Co. covering the life science tools and diagnostics space. Mr. Notarianni received his B.S. in Business Administration from Marquette University.
MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. Its product portfolio categories include Wound Care Products, and Surgical and Other Products. Its Wound Care Products include EPIFIX, EPICORD and EPIEFFECT, which are all marketed for external use, such as in advanced wound care applications. Its Surgical and Other product offering includes AMNIOFIX, AMNIOCORD and AMNIOEFFECT, which are positioned for use in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The Company's platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc.
MIMEDX GROUP, INC. 
